Genovate Biotechnology Valuation

Q: What is the Fair Price of 4130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

4130 (NT$21.8) is trading below our estimate of [[fair value]] (NT$136.61)

Is 4130 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4130 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4130 (NT$21.8) is trading below our estimate of fair value (NT$136.61)

Significantly Below Fair Value: 4130 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4130?

Key metric: As 4130 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4130. This is calculated by dividing 4130's market cap by their current earnings.
What is 4130's PE Ratio?
PE Ratio	90x
Earnings	NT$27.30m
Market Cap	NT$2.46b

4130 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.7x
Enterprise Value/EBITDA	31.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 4130's PE Ratio compare to its peers?

The above table shows the PE ratio for 4130 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.5x
8279 Syngen BiotechLtd	14.9x	n/a	NT$3.6b
6817 Winston Medical Supply	10.9x	n/a	NT$1.6b
4747 Johnson Chemical Pharmaceutical Works	37.9x	n/a	NT$3.1b
1762 Chunghwa Chemical Synthesis & Biotech	30.4x	n/a	NT$3.0b
4130 Genovate Biotechnology	90x	n/a	NT$2.5b

Price-To-Earnings vs Peers: 4130 is expensive based on its Price-To-Earnings Ratio (90x) compared to the peer average (23.5x).

Price to Earnings Ratio vs Industry

How does 4130's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 4130 is expensive based on its Price-To-Earnings Ratio (90x) compared to the TW Pharmaceuticals industry average (23x).

Price to Earnings Ratio vs Fair Ratio

What is 4130's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4130 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	90x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4130's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

RBC Bioscience

NT$254.3m

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia.

6848

NT$19.60

-0.5%

29.8%

YungShin Global Holding

NT$15.4b

Through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics in Taiwan, Mainland China, Japan, and the United States.

3705

NT$57.90

8.2%

27.1%

Cenra

NT$6.0b

Engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals.

1701

NT$21.15

-8.8%